Lung-I Cheng | Head of Global Value & Access, Cell Therapies
Takeda Pharmaceutical Company Ltd.

Lung-I Cheng, Head of Global Value & Access, Cell Therapies, Takeda Pharmaceutical Company Ltd.

Lung-I Cheng, PhD, is Head of Global Value & Access, Cell Therapies at Takeda Pharmaceuticals. In this role, he leads the access strategy for Takeda's portfolio of cell therapy assets in oncology. Prior to this, he oversaw the market access efforts for the company's lymphoma franchise, leading to multiple successful launches and reimbursements. Lung-I specializes in end-to-end access strategy development for innovative medicines, from price optimization, evidence generation, to value demonstration. He began his career at Amgen as a health economist and worked on pipeline, launch, and inline assets in cardiovascular and metabolic diseases.

Appearances:

´╗┐

Day 3: Friday 21st May 2021 - Commercialisation, Pricing & Access @ 13:30

Overcoming pain points in the CGT value chain by creating a scalable and collaborative ecosystem

┬ĚThis session will feature interviews with leaders in Biopharma and logistics as they discuss their pain points as they move cell and gene therapies into commercialization.
last published: 10/May/21 08:45 GMT

back to speakers